INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 25 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $5,420,332,000 | +3.0% | 8,362,000 | -5.4% | 0.01% | -20.0% |
| Q4 2020 | $5,261,461,000 | -4.9% | 8,837,000 | +9.8% | 0.01% | +25.0% |
| Q3 2020 | $5,532,883,000 | +259.9% | 8,049,000 | +275.6% | 0.01% | +166.7% |
| Q2 2020 | $1,537,388,000 | -15.7% | 2,143,000 | 0.0% | 0.00% | -25.0% |
| Q1 2020 | $1,823,243,000 | +54.8% | 2,143,000 | +140.8% | 0.00% | +100.0% |
| Q4 2019 | $1,177,568,000 | -36.9% | 890,000 | -57.2% | 0.00% | -33.3% |
| Q3 2019 | $1,867,602,000 | +7.1% | 2,078,000 | +17.9% | 0.00% | 0.0% |
| Q2 2019 | $1,744,524,000 | – | 1,763,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $34,742,000 | 1.33% |
| PenderFund Capital Management Ltd. | 5,000,000 | $3,839,000 | 0.98% |
| Context Capital Management, LLC | 7,485,000 | $4,494,000 | 0.62% |
| Opti Capital Management, LP | 7,000,000 | $4,250,000 | 0.47% |
| Soros Fund Management | 32,298,000 | $19,611,000 | 0.37% |
| Shaolin Capital Management LLC | 7,000,000 | $4,175,000 | 0.29% |
| Weiss Asset Management LP | 3,500,000 | $2,084,000 | 0.09% |
| CSS LLC/IL | 2,825,000 | $1,681,000 | 0.06% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $137,000 | 0.02% |
| LAZARD ASSET MANAGEMENT LLC | 25,000,000 | $15,009,000 | 0.02% |